Zdrowie i gospodarka · 04/05/2023
FDA Establishes Public Docket for Comments on Nitrosamine Impurities in Human Drug Products
The FDA is soliciting public comments on the identification, assessment, and control of N-nitrosamine impurities in human drug products, with a focus on scientific and regulatory considerations.
Source: Federal Register — Food and Drug AdministrationOpen original release →